StockNews.com Initiates Coverage on Cara Therapeutics (NASDAQ:CARA)

Equities research analysts at StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARAGet Free Report) in a report released on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of NASDAQ:CARA opened at $0.26 on Friday. The company’s fifty day moving average is $0.29 and its two-hundred day moving average is $0.33. The company has a market cap of $14.15 million, a P/E ratio of -0.15 and a beta of 0.64. Cara Therapeutics has a 12-month low of $0.24 and a 12-month high of $1.17.

Institutional Trading of Cara Therapeutics

Hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in Cara Therapeutics during the third quarter valued at approximately $29,000. FMR LLC lifted its position in Cara Therapeutics by 18.5% in the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 32,789 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN boosted its stake in shares of Cara Therapeutics by 6.6% during the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 120,660 shares during the period. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Cara Therapeutics

(Get Free Report)

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

Read More

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.